In contrast to RIPK1, we found a differential expression of RIPK3 that largely correlated with the sensitivity of the tumor cell lines to TRAIL/zVAD/CHX or TNF/zVAD/CHX (Figure 3c, (Additional file 4: Figure S2b), Figure 1a and b). This evidence concerns the gene RIPK3 and neoplasm.